All In Biotech

Drug Trial Radar · NCT07228832

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Nov 18, 2025

Primary completion

May 31, 2028

Study completion Nov 30, 2029

Sponsor

Lead sponsor
Summit TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer(HARMONi-GI3)

Conditions

  • Metastatic Colorectal Cancer (CRC)

Interventions

  • Drug: Ivonescimab InjectionDrug

    Subjects will receive Ivonescimab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles. Afterward, Ivonescimab plus Leucovorin and 5-Fluorouracil will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) for up to 2 years.

  • Drug: Bevacizumab InjectionDrug

    Subjects will receive bevacizumab Plus mFOLFOX6 (Oxaliplatin, Leucovorin and 5-Fluorouracil) via intravenous infusion (IV) Q2W, up to 8 cycles in treatment periods per the randomization schedule. Afterward, bevacizumab Plus 5-FU and Leucovorin will be used for maintenance treatment (administered on Day 1 of each cycle, Q2W) up to 2 years.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFS by IRRC based on RECIST v1.1Time frame: Up to approximately 2.5 years

Locations

243 sites in 15 countries. Site status is shown where the registry gives one.

  • Clinical Study Site

    Mobile, Alabama · Recruiting

  • Clinical Study Site

    Tuscaloosa, Alabama · Recruiting

  • Clinical Study Site

    Goodyear, Arizona · Recruiting

  • Clinical Study Site

    Beverly Hills, California · Recruiting

  • Clinical Study Site

    Beverly Hills, California · Recruiting

  • Clinical Study Site

    Cerritos, California · Recruiting

  • Clinical Study Site

    Corona, California · Recruiting

  • Clinical Study Site

    Duarte, California · Recruiting

  • Clinical Study Site

    Fountain Valley, California · Recruiting

  • Clinical Study Site

    Huntington Beach, California · Recruiting

  • Clinical Study Site

    Irvine, California · Recruiting

  • Clinical Study Site

    Irvine, California · Recruiting

  • Clinical Study Site

    Los Angeles, California · Recruiting

  • Clinical Study Site

    Los Angeles, California · Recruiting

  • Clinical Study Site

    Los Angeles, California · Recruiting

  • Clinical Study Site

    Murrieta, California · Recruiting

  • Clinical Study Site

    Oakland, California · Recruiting

  • Clinical Study Site

    Orange, California · Recruiting

  • Clinical Study Site

    Pasadena, California · Recruiting

  • Clinical Study Site

    Roseville, California · Recruiting

  • Clinical Study Site

    San Francisco, California · Recruiting

  • Clinical Study Site

    Santa Clara, California · Recruiting

  • Clinical Study Site

    Stanford, California · Recruiting

  • Clinical Study Site

    Torrance, California · Recruiting

  • Clinical Study Site

    Upland, California · Recruiting

  • Clinical Study Site

    Vallejo, California · Recruiting

  • Clinical Study Site

    West Hollywood, California · Recruiting

  • Clinical Study Site

    Aurora, Colorado · Recruiting

  • Clinical Study Site

    Denver, Colorado · Recruiting

  • Clinical Study Site

    Highlands Ranch, Colorado · Recruiting

  • Clinical Study Site

    Lone Tree, Colorado · Recruiting

  • Clinical Study Site

    Hartford, Connecticut · Recruiting

  • Clinical Study Site

    New Haven, Connecticut · Recruiting

  • Clinical Study Site

    Norwich, Connecticut · Recruiting

  • Clinical Study Site

    Newark, Delaware · Recruiting

  • Clinical Study Site

    Hialeah, Florida · Recruiting

  • Clinical Study Site

    Miami, Florida · Recruiting

  • Clinical Study Site

    Miami Beach, Florida · Recruiting

  • Clinical Study Site

    Ocala, Florida · Recruiting

  • Clinical Study Site

    Orlando, Florida · Recruiting

Showing 40 of 243 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.